Regen BioPharma’s QQ1 2025 results underscore the challenges typical of an early-stage biotechnology company with minimal near-term commercial revenue. Revenue stood at 59,065 USD for the quarter, but there was no reported gross profit, as cost of revenue matched revenue in the period. Operating expenses were 131,602 USD, driving an operating loss of 72,537 USD and an EBITDA of -422,824 USD. Total other income and expenses weighed heavily on the bottom line, with -388,278 USD of net other income/expenses, resulting in a net loss of -460,815 USD or -0.029 per share on a diluted basis. Cash burn was evident in the cash flow statement, with net cash used in operating activities at -66,380 USD and free cash flow of -66,380 USD. The company ended the period with a modest cash balance of 135 USD and a starting cash balance of 716 USD, signaling a razor-thin liquidity runway.
The balance sheet presents pronounced leverage and a fragile liquidity position: total current liabilities of 5,797,913 USD dwarf current assets of 179,052 USD, yielding an extremely weak current ratio (~0.03). The company carries a short-term debt balance of 873,137 USD and a sizable deferred revenue balance of 1,433,531 USD, with stockholders’ equity deeply negative at -5,601,129 USD. These metrics imply a substantial liquidity risk and reliance on external financing to sustain operations.
YoY revenue declined about 0.5%, while net income deteriorated meaningfully, with a YoY decline of 64% and a QoQ decline of approximately 293%. The operating income improved modestly QoQ but remained deeply negative due to non-operating charges. Absent a clear near-term path to meaningful revenue generation or transformative financing/licensing activity, Regen BioPharma remains a high-risk, high-uncertainty investment within the biotech landscape. Management commentary from an earnings call is not available in the provided materials, which limits the ability to corroborate forward-looking guidance or strategic pivots for QQ1 2025.